CeliVax Technology

Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases

Original CeliVax Technology

Antigen Presenting Cells

CeliVax uses B cells, NK cells and monocytes as APCs.

B cells/NK cells/monocytes

  • Cellid developed the world’s first technology of utilizing B cells, NK cells and monocytes as high-efficiency APC.
  • A sufficient amount of B cells, NK cells and monocytes can be easily collected from peripheral blood, which makes the drug manufacturing process fast and robust.
  • With an appropriate adjuvant, B cells, NK cells and monocytes can stimulate T cell activation as efficiently as dendritic cells.